Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development
Andrew Davies(University Hospital Southampton NHS Foundation Trust), Xavier C. Badoux(St George Hospital)
Cited by 63
Related Papers
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells
|New England Journal of Medicine|2004|1.4k
Phase II Study of Lenalidomide and Rituximab As Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
|Journal of Clinical Oncology|2012|153